1,024
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK

ORCID Icon, ORCID Icon, , , , , ORCID Icon, , , ORCID Icon & show all
Pages 279-291 | Received 21 Nov 2023, Accepted 25 Jan 2024, Published online: 19 Feb 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.